9 results about "Viremia" patented technology

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

The application belongs to the technical field of genetic engineering of aquatic animals, and discloses application of fish VDAC2 genes in resisting inflammation reaction induced by aquatic viruses. Experimental data of the application show that the inflammation reaction caused by SVCV can be significantly inhibited by using VDAC2 inhibitor Dids or knocking down VDAC2, and the survival rate of fish after infection with the SVCV virus can be effectively improved, so VDAC2 plays an important role in regulating the inflammation reaction induced by the spring viremia of carp virus. The application provides a new drug target for virus prevention and control in the field of aquatic products, and has important significance for prevention and control of aquatic viruses.

The invention relates to the technical field of medical biological detection, provides a novel application of HBV RNA, particularly relates to an application in preparation of an LLV screening kit, and further provides a kit and a detection method for performing LLV screening by quantitative detection of HBV RNA. HBV RNA can reflect cccDNA in the liver of a chronic hepatitis B patient and the level of transcriptional activity of cccDNA. In disease assessment and follow-up visit of chronic hepatitis B patients, as a non-invasive assessment means, serum HBV RNA level dynamic monitoring is helpful for early recognition of potential LLV patients, so that the patients are intervened as soon as possible and disease progression is prevented in clinical diagnosis and treatment of chronic hepatitis B.

The application discloses application of deoxycholic acid in preparation of a medicine or additive for resisting aquatic virus infection, wherein the aquatic virus is a spring viremia of carp virus and / or infectious hematopoietic necrosis virus. Experimental data show that the deoxycholic acid can significantly inhibit the proliferation of the spring viremia of carp virus and the infectious hematopoietic necrosis virus in vivo and in vitro, and effectively improve the survival rate of fish after being infected with the two viruses, so that the deoxycholic acid can be developed as a medicine and a feed additive for preventing and controlling viruses in the field of aquaculture, and has important significance for preventing and controlling aquatic viruses.

The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVAG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented development of viremia. rVSVAG-MARV-GP vaccination induced MARV GP-specific serum IgG, and virus-neutralizing activity in serum was detectable in animals vaccinated with the highest doses. Vaccination may occur via intramuscular administration, oral administration, or intranasal administration.

The present application relates to aquatic animal antiviral technology field, especially to a kind of anti-carp edema virus protein of brocade carp and its application.The amino acid sequence of the anti-carp edema virus protein provided in the present application is shown as SEQ ID NO.1, and the 1-27th amino acid of the amino acid sequence is signal peptide.The nucleotide sequence of the brocade carp Viperin gene for encoding the anti-carp edema virus protein is shown as SEQ ID NO.2.Injection of the Viperin recombinant protein obtained in the present application can improve the immune gene expression of brocade carp infected with carp edema virus.Moreover, after injection of the Viperin recombinant protein obtained in the present application, the content of carp edema virus in gill tissue of brocade carp is significantly lower than that of the control group, and the anti-carp edema virus protein provided in the present application has a significant inhibitory effect on brocade carp infected with carp edema virus.

The invention relates to the technical field of medical biological detection, provides new application, particularly application in preparation of an LLV screening kit, and further provides a kit and a detection method for performing LLV screening by specific quantitative detection. The cccDNA in the liver of a chronic hepatitis B patient and the level of transcriptional activity of the cccDNA can be In disease assessment and follow-up visit of chronic hepatitis B patients, as a non-invasive assessment means, serum level dynamic monitoring contributes to early recognition of potential LLV patients, so that the patients are intervened as soon as possible and disease progression is prevented in clinical diagnosis and treatment of chronic hepatitis B.